COVID-19 Updates

The GBS|CIDP Foundation is committed to sharing the most accurate information from the world’s leading experts, many from our Global Medical Advisory Board. The COVID-19 situation changes daily and we will continue to share updates that are vetted by the experts in GBS. In addition, we are in regular contact with the FDA representing the patient voice in the top-level decision-making. We understand that there are many opinions creating confusion so please consider the source of your information before drawing conclusions.  As always, all decisions should be made with your personal physician based on your own health. The information below is the most up to date available on Covid-19, vaccines, and the GBS|CIDP Community

  • Update on COVID-19 Vaccine

    This statement is provided by the GBS|CIDP Foundation Global Medical Advisory Board.  We also encourage you to contact your healthcare provider about whether it would be a good idea for you to have a COVID-19 vaccine. There has been much discussion about COVID-19 vaccines for individuals who are “immunocompromised.” GBS and CIDP and immune-mediated disorders….

    Read More

  • GMAB Statement on Vaccine Boosters and the GBS|CIDP Community

    This statement is provided by the GBS|CIDP Foundation Global Medical Advisory Board.  We also encourage you to contact your healthcare provider about whether it would be a good idea for you to have a third COVID19 vaccine dose. There has been much discussion about third shots or “booster shots” of certain COVID19 vaccines for individuals…

    Read More

  • Pfizer-BioNTech COVID-19 Vaccine for children ages 5 through 11 years

    On October 29, 2021, the U.S. Food and Drug Administration authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children ages 5 through 11 years.  The vaccine was studied in approximately 3,100 children aged 5 through 11, without reported serious side effects. No cases of myocarditis occurred during…

    Read More

  • Global Medical Advisory Board (GMAB) Statement on Vaccines

    COVID19 vaccines are different from flu vaccines. We are not seeing evidence that COVID19 vaccines are more likely to cause GBS, even in individuals who have had GBS brought on by other vaccines. Therefore, we do not see prior GBS as a reason not to get a COVID19 vaccine. 

    Read More

  • Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine

    Read the full article, Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2, (Jama Neurology).

    Read More

  • Third dose of Vaccination for Immune Suppressed Patients

    Third dose of Vaccination for Immune Suppressed Patients August 19, 2021 A statement from our Global Medical Advisory Board On August 12th, the FDA authorized that a third dose of COVID-19 mRNA vaccines (Pfizer and Moderna) may be given to patients who are moderately or severely immunocompromised.  Patients who are considered immune-suppressed are those who…

    Read More

  • FDA Warning for Guillain–Barre Syndrome and the Johnson & Johnson COVID-19 Vaccine

    A Statement from the Foundation Global Medical Advisory Board The Washington Post and New York Times published on July 12, 2021 articles of a report by the FDA regarding cases of purported GBS after receiving the Johnson and Johnson COVID 19 vaccine.  Approximately 100 reports of suspected GBS were experienced by 12.8 million subjects who…

    Read More

  • Statement on Vaccines and GBS

    Statement on Vaccines and GBS June 18, 2021 There is no evidence at the present time to suggest that ANY of the vaccines is associated with GBS in any significant numbers (with data only on AZ, Pfizer and Moderna from the UK). Multiple international surveillance systems are looking specifically for GBS as it is designated…

    Read More

  • Ask The Experts Episode 9 – COVID-19 Vaccines and the GBS|CIDP Community

    Ask The Experts Episode 9 – COVID-19 Vaccines and the GBS|CIDP CommunityFeaturing Dr. Peter Donofrio, Chairman of the Global Medical Advisory Board

    Read More

  • COVID-19 Vaccines and the GBS|CIDP Community

    The GBS|CIDP Foundation has received many questions about COVID-19 and its relationship to Guillain-Barré syndrome and CIDP.

    Read More

  • Foundation Global Medical Advisory Board statement on COVID vaccines for CIDP and MMN

    No instances of CIDP or MMN were seen during clinical trials of the two vaccines. Neither the Centers for Disease Control and Prevention (CDC) nor the Food and Drug Administration (FDA) recommends against administration of the Covid 19 vaccine in patients with CIDP or MMN. One must keep in mind that the Covid Vaccine has…

    Read More

  • Dr. A.S. Fauci Corrects Previous Statement Regarding COVID-19 Vaccines & GBS

    As a follow up to the Foundation’s published article from Dec. 20, 2020, “An Open Letter to Dr. A.S. Fauci, Director NIAID, NIH,” on January 15, 2021, Neurology Today published the following article “No Excess Risk for Neurologic Events Observed to Date from COVID-19 Vaccines.”   Read the full article…

    Read More

  • Persons who have previously had GBS may receive an mRNA COVID-19 vaccine

    Adults of any age with certain underlying medical conditions are at increased risk for severe illness from the virus that causes COVID-19. mRNA COVID-19 vaccines may be administered to people with underlying medical conditions provided they have not had a severe allergic reaction to any of the ingredients in the vaccine. The following information aims to help people in the…

    Read More

  • An Open Letter to Dr. A.S. Fauci, Director NIAID, NIH

    (Please see the following open letter statement authored by members of the GBS|CIDP Foundation International medical community as referenced.) As clinician/scientists who have spent careers studying GBS, we are concerned that your statement on the “New Normal” television show about GBS and the COVID vaccine will have unintended consequences. Your statement is already all over…

    Read More

  • FDA approved package insert for Pfizer-Biontech COVID-19 vaccine, no mention of GBS as risk

    This information is a public document and has been forwarded to the Foundations by our key opinion leaders in the GBS medical community. Of note, there is no mention of GBS in the vaccine insert, not as a risk nor as a vaccine to avoid for those who have had GBS or CIDP or are…

    Read More

  • GBS|CIDP Foundation staff & patients collaborate with FDA

    By Lisa Butler In 2020 as the Foundation worked with the FDA, for the first time, what I feel is most notable – and praiseworthy –  is their straightforward adherence to science, and their tremendous efforts to bring the patient perspective into the decision-making process. I feel even more confident in the leadership of the…

    Read More

  • Statement from Professor Lunn in Reference to Newest Research on COVID-19, GBS, and Vaccines

    In reaction to recent research published in Brain (click here to read more), Professor Lunn has offered this guidance in regards to our community.

    Read More

  • New Study Reveals No Association Between COVID-19 and Guillain-Barré Syndrome

    A UK based epidemiological study, linked below, has found no causal association between COVID-19 infection and Guillain-Barré syndrome. This means that GBS developing at the same time or close to that of COVID-19 is most likely coincidental.

    Read More

  • APLUS Statement on the State of Plasma

    The American Plasma Users Coalition (APLUS) recognizes and applauds the recent statements from the White House that emphasize the importance of plasma and how essential plasma donors are to the healthcare system. This statement rings true for convalescent plasma that may help countless patients battling COVID-19 and is especially true for people all over the…

    Read More

  • Wrap Up With A Win – Awareness Month’s Advocacy Week Brings Legislative Victories

    Our 2020 May Awareness Month went digital this year, but that did not stop nearly 100 advocates across the US from participating in virtual advocacy through the Advocacy Action Center. THANK YOU to everyone who took the time to create a letter for Members of Congress. Together, we make our voices heard by lawmakers and…

    Read More

  • May is GBS|CIDP Awareness Month

    May of 2020 has brought unprecedented challenges and changes, the world over. We hope you find comfort in knowing that the GBS|CIDP Foundation has made every effort to continue to Educate our patients in new and innovative ways.

    Read More

  • Covid19, Ask the Expert

    COVID-19 Ask the Experts with Dr. Ken Gorson, part of our educational series featuring medical experts from the Foundation’s Global Medical Advisory Board.

    Read More

  • The COVID-19 Rare Disease Critical Needs Non-Medical Assistance Fund from The National Organization of Rare Disorders

    The National Organization of Rare Disorders (NORD) launched a COVID-19 Critical Relief Program to provide much-needed assistance to members of the rare community affected by the current pandemic. The program provides financial relief that may be utilized to support critical, non-medical needs.  The COVID-19 Critical Needs Non-Medical Assistance Fund provides eligible individuals impacted by the…

    Read More

  • Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19

    Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19

    Read More

  • What is Convalescent Plasma?

    By Dr. David Saperstein Antibodies (also known as immunoglobulins) play an important role in health and illness. Many of you regularly receive intravenous immunoglobulin (IVIG) to treat your autoimmune disease. Flooding a person’s system with antibodies from normal, healthy individuals can reverse problems caused by abnormally overactive immune systems. However, providing antibodies that fight a specific infection can…

    Read More

  • Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

    Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.

    Read More

  • Work Continues for CSL Behring During the Pandemic

    Patient groups praise U.S. guidelines that designate plasma centers, manufacturing sites as essential. See full article

    Read More

  • Update on Home Infusion & Medicare During COVID-19 Pandemic

    Earlier this week, the Center for Medicare and Medicaid Services (CMS) released new guidelines for the coverage of home infusion during the COVID-19 pandemic. The new guidelines allow for more flexibility for patients and their physicians to decide the best setting for ongoing treatments. Given your current situation, you may be able to access home…

    Read More

  • NHC Webinar – Coronavirus Preparedness for People with Chronic Diseases, What Caregivers Need to Know

    COVID-19 is causing significant concerns globally. Watch a recording of this March 27 Webinar produced by the National Health Council, for caregivers of patients with chronic diseases. The webinar discusses how caregivers can best avoid the illness and care for themselves while also helping those who are not well.  https://nationalhealthcouncil.org/coronavirus-preparedness-for-people-with-chronic-diseases-what-do-caregivers-need-to-know/

    Read More

  • Advocating for Plasma Donations and Home Infusion

    The GBS|CIDP Foundation International recently led the American Plasma Users Coalition (APLUS) in creating a letter to federal and state agencies regarding two important topics to our community: plasma donations and home infusion. The Foundation and APLUS want to make sure that lawmakers are aware that plasma collection centers are considered “essential” according to the…

    Read More

  • COVID-19 FAQ from GBS|CIDP & Variant Community

    Informing our GBS|CIDP Foundation community is our top priority.  This week we have received a number of questions regarding COVID-19 through email, phone calls, and our social media channels.  Two of the primary concerns are addressed below. The answers are provided by the GBS|CIDP Foundation International Global Medical Advisory Board. As we continue to navigate…

    Read More

  • Update on Coronavirus (COVID-19) – March 19th

    Dear GBS|CIDP Community, We know that this is a challenging time for everyone as the news of the pandemic is evolving each day. Please know we are here for you and the GBS|CIDP Foundation International is committed to addressing your concerns as accurately and efficiently as possible. A number of our members have reached out…

    Read More

  • NHC Webinar – Coronavirus Preparedness for People with Chronic Diseases Webinar

    COVID-19 is causing significant concerns globally. Watch a recording of this March 13 Webinar produced by the National Health Council, for patients with chronic diseases. The webinar discusses how patients can best avoid the illness, and what to do if they feel sick. Watch Webinar here or visit NHC website for more information.

    Read More

  • A Statement from Executive Director, Lisa Butler, with regard to COVID-19 and Planning Ahead

    We are all in this together, and the GBS|CIDP Foundation International will make every effort to keep our community informed and updated.

    Read More

  • Resource from PPTA Regarding COVID-19

    The Plasma Protein Therapeutics Association (PPTA) has provided a statement specific to plasma protein therapies in light of the COVID-19 pandemic. CLICK HERE to read the statement. The PPTA notes that their Pathogen Safety Steering Committee continues to monitor the situation and is currently working on a broader update for the community. We will share these…

    Read More

  • A statement from the GBS|CIDP Foundation regarding the COVID-19

    The coronavirus COVID-19 situation is evolving rapidly. In the interest of concerns and questions that the Foundation is receiving regarding the spread of the coronavirus COVID-19, the GBS|CIDP Global Medical Advisory Boards offers the following statement: GBS, CIDP and variants will not put patients at any higher risk of contracting the COVID-19, but those who…

    Read More